Sacituzumab govitecan, an FDA-approved drug for breast cancer, has shown encouraging results as a potential treatment for advanced uterine cancer in a Phase II clinical trial . The study included 50 patients whose disease had progressed after standard therapies. Researchers found that 70% of participants experienced some degree of tumor shrinkage, while 28% achieved a significant response with tumors shrinking by at least 30%. These results compare favorably with current third-line treatment options, which typically produce meaningful responses in fewer than 15% of patients.
The drug works by targeting Trop-2, a protein commonly found on uterine cancer cells, enabling chemotherapy to be delivered directly to tumors while limiting damage to healthy tissues. Side effects, primarily bone marrow suppression and gastrointestinal symptoms, were generally manageable. The findings offer new hope for patients with treatment-resistant uterine cancer, and a larger Phase III trial is underway to confirm the treatment’s benefits and potential role in standard care.